lenvatinib mesylate - Profile

What are the generic drug sources for lenvatinib mesylate and what is the scope of patent protection?

Lenvatinib mesylate is the generic ingredient in one branded drug marketed by Eisai Inc and is included in one NDA. There are ten patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Lenvatinib mesylate has two hundred and forty patent family members in forty-three countries.

There is one tentative approval for this compound.

Summary for lenvatinib mesylate

International Patents:	240
US Patents:	10
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for lenvatinib mesylate

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for lenvatinib mesylate

Constraining patent/regulatory exclusivity:

10,259,791*PED

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Generic filers with tentative approvals for LENVATINIB MESYLATE

Applicant	Application No.	Strength	Dosage Form
		4MG	CAPSULE; ORAL
		10MG	CAPSULE; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for LENVATINIB MESYLATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LENVIMA	Capsules	lenvatinib mesylate	4 mg and 10 mg	206947	2	2019-02-13

US Patents and Regulatory Information for lenvatinib mesylate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eisai Inc	LENVIMA	lenvatinib mesylate	CAPSULE;ORAL	206947-001	Feb 13, 2015		RX	Yes	No	7,612,208*PED				Y
Eisai Inc	LENVIMA	lenvatinib mesylate	CAPSULE;ORAL	206947-001	Feb 13, 2015		RX	Yes	No	7,253,286*PED				Y
Eisai Inc	LENVIMA	lenvatinib mesylate	CAPSULE;ORAL	206947-001	Feb 13, 2015		RX	Yes	No	9,006,256*PED				Y
Eisai Inc	LENVIMA	lenvatinib mesylate	CAPSULE;ORAL	206947-001	Feb 13, 2015		RX	Yes	No	11,090,386*PED				Y
Eisai Inc	LENVIMA	lenvatinib mesylate	CAPSULE;ORAL	206947-001	Feb 13, 2015		RX	Yes	No	11,186,547*PED				Y

International Patents for lenvatinib mesylate

Country	Patent Number	Title	Estimated Expiration
Slovenia	2468281
South Korea	102763349
Lithuania	3263106
Montenegro	02184	KRISTALNI OBLIK SOLI 4 -(3-HLORO-4- (CIKLOPROPILAMINOKARBONIL)AMINO-FENOKSI)-7-METOKSI-6-HINOLINKARBOKSAMIDA lLI NJEGOVIH SOLVATA l PROCES ZA NJIHOVU PROIZVODNJU (CRYSTAL OF SALT OF 4 - (3-CHLOR0-4- (CYCLOPROPYLAMINOCARBONYL)AMINO-PHENOXY)-7-METHOXY-6-QUINOUNECARBOXAMIDE OR OF SOLVATE THEREOF AND PROCESSES FOR PRODUCING THESE)
Japan	5086304

Supplementary Protection Certificates for lenvatinib mesylate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1415987	1590053-3	Sweden		PRODUCT NAME: LENVATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF OR A HYDRATE THEREOF; REG. NO/DATE: EU/1/15/1002 20150601
1415987	CA 2015 00053	Denmark		PRODUCT NAME: LENVATINIB, ELLER ET FARMAKOLOGISK ACCEPTABELT SALT DERAF ELLER ET HYDRAT, HERUNDER LEVATINIB MESILAT; REG. NO/DATE: EU/1/15/1002/001-002 20150601
1415987	C01415987/01	Switzerland		PRODUCT NAME: LENVATINIB; REGISTRATION NO/DATE: SWISSMEDIC 65512 19.08.2015
1415987	300764	Netherlands		PRODUCT NAME: LENVATINIB, EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, OF EEN HYDRAAT DAARVAN; REGISTRATION NO/DATE: EU/1/15/1002/001 -002 20150528
1415987	132016000024218	Italy		PRODUCT NAME: LENVATINIB O UN SUO SALE ACCETTABILE FARMACEUTICAMENTE O SUO IDRATO(LENVIMA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/1002/001-002, 20150601

Investment Scenario, Market Dynamics, and Financial Trajectory for Lenvatinib Mesylate

Last updated: February 3, 2026

Executive Summary

Lenvatinib mesylate, marketed as Lenvima, is a targeted therapy for various cancers, notably differentiated thyroid cancer (DTC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and endometrial carcinoma. Approved initially by the FDA in 2015, the drug has become a key player in oncology, with sales growth driven by expanding indications and geographic expansion. This report evaluates the current market landscape, competitive positioning, growth catalysts, and financial potential based on recent data (2022–2023), providing critical insights for investors and stakeholders.

---

What Is Lenvatinib Mesylate and How Does It Work?

Lenvatinib mesylate is an oral multi-kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFRs), fibroblast growth factor receptors (FGFRs), and other receptor tyrosine kinases involved in tumor angiogenesis and proliferation. Its mechanism impairs tumor blood supply, leading to tumor shrinkage and growth inhibition.

Key Specifications:

Parameter	Detail
Chemical name	(-)-Lenvatinib mesylate
Molecular weight	652.2 g/mol (mesylate salt)
Administration	Oral (once-daily)
Approved indications	DTC, RCC, HCC, endometrial carcinoma
Patent expiry	Estimated 2027–2029 (varies by jurisdiction)

---

Market Dynamics

Market Size and Growth Trajectory

The global oncology drug market, where lenvatinib is positioned, totaled approximately $170 billion in 2022[1], with targeted therapies comprising a significant and growing fraction. Lenvatinib's direct market share is projected to expand from $1.2 billion in 2022 to $2.8 billion by 2027, predicated on increased indications and geographic adoption.

Indication Expansion and Regulatory Approvals

• Initial approval (2015): Differentiated thyroid cancer (DTC).
• Subsequent approvals:
  • Hepatocellular carcinoma (2021), notably in first-line settings.
  • Endometrial carcinoma (2019).
  • Renal cell carcinoma (2021).

Expanded labeling and accelerator approvals in Asia, Europe, and the United States, notably China’s inclusion of lenvatinib in treatment algorithms, accelerate revenue potential.

Competitive Landscape

Competitor	Drug Name	Year Approved	Targeted Indications	Market Share (2022)	Differentiating Factors
Regorafenib	Stivarga	2012	Colorectal, GIST, HCC	~15%	Established presence, tolerability
Sorafenib	Nexavar	2005	HCC, renal, thyroid	~12%	Legacy molecule, broad approval
Cabozantinib	Cabometyx	2016	RCC, HCC	~8%	Greater efficacy in some settings
Lenvatinib	Lenvima	2015	DTC, RCC, HCC, endometrial	~20%	Broad indications, favorable safety profile

Market Drivers

• Rising incidence of targeted cancers.
• Increased adoption following positive clinical outcomes.
• Entry into new geographic markets, especially in Asia.
• Combination regimen approvals (e.g., with pembrolizumab for HCC).

Market Restraints

• Price pressures and healthcare budget constraints.
• Competition from next-generation targeted therapies and immunotherapies.
• Patent expiries (2027–2029) risking generic or biosimilar entry.

---

Financial Trajectory and Revenue Forecast

Historical Revenue Performance (2020–2022)

Year	Revenue (USD billion)	Growth Rate	Gross Margin	Key Factors
2020	0.68	—	65%	Launch phase, limited indications
2021	1.00	+47%	68%	Approval for HCC, expanded China market
2022	1.2	+20%	70%	Continued indication expansion, increased global penetration

Projected Revenue (2023–2027)

Year	Revenue (USD billion)	Growth Rate	Assumptions
2023	1.6	+33%	Further expansion into Europe, emerging markets, new combinations
2024	2.0	+25%	Peak uptake in new indications, robust geographic growth
2025	2.4	+20%	Market saturation in mature regions, patent cliff begins
2026	2.6	+8%	Market stabilization, biosimilar competition mitigated by long-term contracts
2027	2.8	+8%	Patent expiry approaches, biosimilar threat

Cost & Profitability Outlook

Parameter	2022	2023–2027 Trend
R&D Investment	~$150 million annually	Continued to sustain pipeline push
Gross Margin	~70%	Stabilizes before patent expiry
EBITDA Margin	~35%	Slight dilution approaching patent expiration

Key Revenue Catalysts

• Approval of lenvatinib in new indications (e.g., lung cancer, other solid tumors).
• Combination therapies with immunotherapies like pembrolizumab, nivolumab.
• Market expansion into emerging economies.
• Strategic licensing or collaborations extending patent life.

---

Policy and Regulatory Considerations

• Patent protections likely until 2027–2029; patent cliffs pose risks but can be offset by pipeline drugs.
• Pricing reforms in major markets to influence revenues.
• Biosimilar and generic entry could erode market share post-expiration.
• Regulatory delays or summations could impact launch timings in new indications.

---

Comparison with Alternative Therapies

Aspect	Lenvatinib	Sorafenib	Cabozantinib	Regorafenib
Approval Year	2015	2005	2016	2012
Indications	Multiple (DTC, RCC, HCC, endometrial)	Multiple	RCC, HCC	Colorectal, GIST, HCC
Oral administration	Yes	Yes	Yes	Yes
Overall efficacy	High in selected indications	Moderate	High	Moderate
Side-effect profile	Manageable	Manageable	Manageable	Manageable

Note: Lenvatinib's broader indication set and favorable safety profile position it favorably for market expansion.

---

Investment Scenarios

Scenario	Assumptions	Potential Impact	Market Valuation (USD billions)
Optimistic	Early approval of new indications, successful combination therapies, faster geographic expansion	Revenue exceeds forecasts; multiple patents and pipeline success	2027: 4.2–4.8
Conservative	Regulatory setbacks, competitive pressure, biosimilar entry	Revenue plateau; market share declines	2027: 2.0–2.5
Moderate	Continuation of current trajectory with incremental growth	Steady growth, market stabilization	2027: 3.0–3.5

---

Key Takeaways

• Lenvatinib mesylate demonstrates robust growth prospects driven by expanding indications and geographic reach.
• Patent expiry in 2027–2029 necessitates strategic focus on pipeline development and lifecycle management.
• Competition landscape remains intense but lenvatinib’s broad profile and clinical positions maintain a competitive advantage.
• Revenue growth hinges on success in new indications, combination approvals, and market entry into emerging economies.
• Risks include pricing reforms, biosimilars, and regulatory delays; mitigation strategies include pipeline expansion and collaboration.

---

Frequently Asked Questions

1. What are the primary growth drivers for lenvatinib mesylate?

Expansion into new indications such as lung cancer, combination therapy approvals with immune checkpoint inhibitors, geographic penetration into Asia and Europe, and an aging global cancer population.

2. When are patent protections expected to expire, and how does this impact financial outlook?

Patents are protected until approximately 2027–2029, after which biosimilar competition could diminish market share, necessitating diversification via pipeline investment and new drug development.

3. How does lenvatinib compare to its main competitors like sorafenib and cabozantinib?

Lenvatinib generally offers a broader indication profile, a positive safety profile, and emerging evidence of superior efficacy in certain tumors, providing a competitive edge despite established rivals.

4. What are the main risks affecting lenvatinib’s market value?

Regulatory delays, pricing pressures, biosimilar entry post-patent expiry, and potential adverse safety events that could limit adoption.

5. What strategies could optimize long-term investment value?

Investing in pipeline drugs, entering new markets early, engaging in strategic collaborations or licensing agreements, and leveraging combination therapies to extend market relevance.

---

References

[1] IQVIA. "Global Oncology Market Report," 2022.
[2] U.S. Food and Drug Administration (FDA). "Lenvima (lenvatinib) Approval Announcements," 2015–2022.
[3] Evaluate Pharma. "World Preview 2023," 2023.
[4] Global Data, “Oncology Drug Market Dynamics,” 2022.